Abstract

223Ra extends overall survival (OS) in pts with bone-metastatic castration-resistant prostate cancer. This study evaluated if the addition of 223Ra to EXE-EVE provided increased benefit over EXE-EVE in pts with bone dominant HR+/HER2- MBC.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Abstract P5-11-02: Dose-escalation study of SAR439859, an oral selective estrogen receptor degrader, in postmenopausal women with estrogen receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer
Mario Campone ... Jeffrey Ming
American Journal of Cancer | VOL. 80
Mario Campone, et. al.Mario Campone ... Jeffrey Ming
14 Feb 2020
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial.
Kevin Kalinsky ...
Journal of Clinical Oncology | VOL. 41
Kevin Kalinsky, et. al.Kevin Kalinsky ...
19 May 2023
First-line treatment with a cyclin-dependent kinase 4/6 inhibitor combined with an aromatase inhibitor for hormone receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: Population-based outcomes for patients treated in Alberta, Canada.
Carla Pires Amaro ... Atul Batra
Journal of Clinical Oncology | VOL. 39
Carla Pires Amaro, et. al.Carla Pires Amaro ... Atul Batra
20 May 2021
Second-line single-agent chemotherapy in human epidermal growth factor receptor 2-negative metastatic breast cancer: A systematic review.
Fabio Puglisi ... Michel A Kroes
Evidence-based Oncology | VOL. 43
Fabio Puglisi, et. al.Fabio Puglisi ... Michel A Kroes
08 Dec 2015
View more papers

More From: Annals of oncology : official journal of the European Society for Medical Oncology

Paper Title
Journal
Date
Author
Efficacy of TIL Therapy in Advanced Cutaneous Melanoma in the Current Immuno-oncology Era: Updated Systematic Review and Meta-analysis
S Martín-Lluesma ... G Coukos
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. -
S Martín-Lluesma, et. al.S Martín-Lluesma ... G Coukos
23 Jul 2024
Exploiting the tumor microenvironment and tumor mechanobiology for the treatment of cancer cachexia
Kostas A Papavassiliou ... Athanasios G Papavassiliou
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. -
Kostas A Papavassiliou, et. al.Kostas A Papavassiliou ... Athanasios G Papavassiliou
23 Jul 2024
Immune Checkpoint Inhibitors in Endometrial Cancer: A Cinderella Story
N Colombo ... M Jalving
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 35
N Colombo, et. al.N Colombo ... M Jalving
22 Jul 2024
Overall survival in first-line HR+/HER2- advanced breast cancer in the era of CDK4/6 inhibitors
Rodrigo Sánchez-Bayona ... Mafalda Oliveira
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 35
Rodrigo Sánchez-Bayona, et. al.Rodrigo Sánchez-Bayona ... Mafalda Oliveira
22 Jul 2024
View more papers